INmune Bio publishes study on INmune’s CORDStrom platform

INmune Bio (INMB) announces a recently published overview of future applications and research areas for mesenchymal stromal cell therapies, such as INmune’s CORDStrom platform. The article, titled, “Fate and Function of Exogenously Administered MSCs: Current Insights and Future Directions,” was published in the peer-reviewed journal Cytotherapy. The article was the result of an invitation-only working party of basic, clinical and translational scientists working on MSCs and available on Cytotherapy’s website, reviews the current knowledge-base and critical gaps in order to formulate experimental questions designed to enhance development of MSC therapies such as the CORDStrom platform. These topics included systemic delivery of MSCs, local and/or depot-delivery, and in vivo persistence.